Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Novartis : to Invest More Than $100 Million to Research, Develop Antimalarials

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2018 | 07:52am CEST

By Pietro Lombardi

Novartis AG (NOVN.EB) said Tuesday that it will invest more than $100 million in the next five years in the research and development of the next-generation antimalarials.

The investment will focus on treatments to tackle resistance to antimalarials currently in use.

"Resistance to treatment presents the biggest threat to the incredible progress that has been made in the fight against malaria in the past 20 years. We cannot afford to wait; this is why we are committing to advance the research and development of next-generation treatments," said Chief Executive Vas Narasimhan.

The company's also said it will work to expand access to pediatric antimalarials and will help implement programs to reinforce health-care systems in four sub-Saharan countries.

Write to Pietro Lombardi at pietro.lombardi@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
09/24NOVARTIS : announces five grant recipients of eXcellence in Ophthalmology Vision..
PU
09/22NOVARTIS : to file for new Lucentis® (ranibizumab) indication in retinopathy of ..
AQ
09/22NOVARTIS : to file for new Lucentis® (ranibizumab) indication in retinopathy of ..
GL
09/22NOVARTIS : New analysis of Novartis Phase III brolucizumab (RTH258) data reinfor..
AQ
09/22NOVARTIS : New analysis of Novartis Phase III brolucizumab (RTH258) data reinfor..
GL
09/22SPARK THERAPEUTICS : Novartis Announces Positive CHMP Opinion for One-Time Gene ..
AQ
09/22SPARK THERAPEUTICS : Novartis Luxturna approved to treat rare retinal disease
AQ
09/22SPARK THERAPEUTICS : Novartis announces positive CHMP opinion for one-time gene ..
AQ
09/22SPARK THERAPEUTICS : Novartis drums up EU launch plans as CHMP gives thumbs up t..
AQ
09/21EMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
More news
News from SeekingAlpha
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
09/24EXPECTED VALUE INVESTING : Diving Deeper On Conatus 
09/24Akcea up 4% premmarket on positive mid-stage data on AKCEA-APO(a)-Lrx 
09/21Sutro Biopharma Prepares Terms For $75 Million U.S. IPO 
09/21New opinions from EMA advisor CHMP 
Financials ($)
Sales 2018 52 459 M
EBIT 2018 12 888 M
Net income 2018 11 683 M
Debt 2018 14 565 M
Yield 2018 3,46%
P/E ratio 2018 14,71
P/E ratio 2019 20,90
EV / Sales 2018 4,43x
EV / Sales 2019 4,27x
Capitalization 218 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 91,5 $
Spread / Average Target 7,1%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-0.63%216 108
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092
AMGEN17.94%132 756